Pathogen Reduction Systems Market to Grow with a CAGR of 8.00% through 2030F
Increasing Awareness and Emphasis on Infection Control
and Rising Incidence of Hospital Associated Infections is expected to drive the
Global Pathogen Reduction Systems Market growth in the forecast period,
2026-2030
According to TechSci Research report, “Pathogen Reduction Systems Market - Global Industry Size, Share,
Trends, Competition Forecast & Opportunities, 2030F”, the Global
Pathogen Reduction Systems Market stood at USD 719.06 million in 2024 and is
anticipated to grow with a CAGR of 8.00% in the forecast period. The
global market for pathogen reduction systems is primarily driven by the
increase in infectious diseases and the growing public awareness of the
importance of safe blood transfusions. Every year, millions of lives are saved
through blood transfusion, which is considered a fundamental pillar of the
modern healthcare system. However, many patients in low- and middle-income
countries still face challenges in accessing timely and secure blood supplies.
Market limitations include concerns about potential
influence or damage to blood cells, as well as the production of harmful
chemical agents during pathogen reduction treatment. The fair remuneration
remains a significant consideration. The evaluation of these innovative
technologies will likely be greatly influenced by ongoing research and
development efforts. The expansion of blood transfusion diagnostics is expected
to create more opportunities, as well as advancements in preventing and
eliminating bacterial infiltration in the blood recipient's body, thus opening
doors for the global pathogen reduction system market.
Despite numerous proactive measures taken to ensure blood
safety, such as strict donor screening, the implementation of new exclusion
criteria, and transfusion hemovigilance, there is still a risk of
transfusion-transmitted infections (TTI). Pathogen reduction systems have been
developed to safeguard the blood supply by inactivating or removing viruses,
bacteria, fungi, or protozoan pathogens. These systems utilize photochemical
processes to render bacteria and viruses inactive, minimizing the risk of infection
in blood products. Various physical, chemical, or photochemical techniques have
been devised to inactivate or reduce pathogens and enhance the safety of the
blood supply. Maintaining platelet activity, crucial for post-transfusion
survival and recovery, is a key aspect of photochemical therapy, which was
specifically developed for platelet therapy.
While the risk factor in pathogen reduction systems is
significantly lower, caution must be exercised when using chemicals in the
pathogen reduction process due to their multiple sites of action. For instance,
cross-linking of lipids in organelles and cell membranes can occur.
Protein-protein interactions between pathogen reduction systems and proteins
can lead to malfunctions in cellular signal transduction, respiratory pathway
deficits, or structural abnormalities. Chemicals attaching to nucleic acids or intercalating
nucleic acid chains can cause errors in transcription, translation, or
replication. The limitations in the market have been significant, with concerns
about the potential influence or damage to blood cells and the production of
harmful chemical agents during pathogen reduction treatment. Fair remuneration
is also a concern. Ongoing research and development will greatly influence the
assessment of these novel technologies. It is predicted that an increase in
blood transfusion diagnostics will create more opportunities. Advancements in
technology to prevent and eliminate bacterial infiltration in blood recipients'
bodies will open up global opportunities in the pathogen reduction system
market.
The risk associated with these systems is minimal, which is
why medical professionals widely adopt them for platelet and plasma reduction
from blood donors. The market is driven by the increasing prevalence of
infectious diseases, rising public awareness of better healthcare facilities,
and the adoption of advanced technologies that result in improved and more
effective pathogen reduction systems. Pathogen reduction systems are utilized to deactivate
viruses and bacteria that may contaminate blood products. These advanced
products utilize ultraviolet rays in the presence of a photosensitizer to act
as a pathogen inactivator. They are essential in the management of blood
transfusion and pathogen inactivation.
Browse over XX market data Figures spread through XX
Pages and an in-depth TOC on "Global Pathogen Reduction Systems Market”
The Global Pathogen Reduction Systems Market is segmented
into type, application, product, end user, regional distribution, and company.
Based on type, Platelet pathogen reduction is the fastest-growing segment in the global pathogen reduction systems market, driven by the increasing need to enhance transfusion safety. Platelet concentrates are particularly vulnerable to contamination, as they are stored at room temperature—a condition that promotes bacterial growth. With their short shelf life and critical role in oncology, intensive care, and surgical procedures, ensuring the safety of platelets has become an urgent priority. The rapid growth of this segment is further fueled by technological innovations and regulatory approvals, especially for systems like the INTERCEPT Blood System by Cerus Corporation. Platelets are more susceptible to transfusion-transmitted infections compared to plasma, making pathogen reduction technologies increasingly essential. Moreover, the rising number of cancer patients and the growing volume of surgeries requiring platelet transfusions are accelerating demand. As a result, the platelet pathogen reduction segment is experiencing significant momentum, emerging as the fastest-growing area within the pathogen reduction systems market.
Based on region, Asia-Pacific is emerging as a rapidly
growing region in the global pathogen reduction systems market, and several
factors contribute to its expanding dominance. The region has witnessed a
significant rise in the number of surgical procedures, trauma cases, and
chronic diseases, which in turn increases the demand for safe blood
transfusions. Countries like China, India, and Japan have large and aging
populations, leading to higher healthcare utilization and a greater need for
blood and blood products. The growing awareness of transfusion-transmitted
infections, especially in developing economies, is driving the adoption of
pathogen reduction technologies. Governments and healthcare institutions are
increasingly investing in improving blood safety standards, backed by global
health organizations promoting infection prevention.
The rapid advancements in healthcare infrastructure,
increased healthcare spending, and favorable regulatory environments are
encouraging the introduction and scaling of advanced medical technologies,
including pathogen reduction systems. Local manufacturing, rising
collaborations with global medical device companies, and supportive public
health policies are also boosting market penetration. The presence of
cost-effective manufacturing and a growing number of clinical research
initiatives further enhance the region’s capacity to implement and scale such
systems. Collectively, these factors are positioning Asia-Pacific as a dominant
and high-growth region in the pathogen reduction systems market.
Major companies operating in Global Pathogen Reduction
Systems Market are:
· Terumo BCT, Inc.
· Macopharma SA.
· Cerus Corporation.
· AngioDynamics, Inc.
· Octapharma AG.
Download Free Sample Report
Customers can also request for 10% free customization
on this report.
“The increasing prevalence of infectious diseases and
growing awareness regarding the necessity of effective blood transfusions serve
as significant drivers for the global pathogen reduction system market. Blood
transfusion is a fundamental pillar of the modern healthcare system, saving
millions of lives annually. However, many hospital patients in low- and
middle-income countries lack access to timely and safe blood supply. The risk
of pathogen and virus development in blood before transfusion remains significantly
high. Nevertheless, the pathogen reduction treatment presents challenges,
including the risk of affecting or harming blood cells and the generation of
toxic chemical agents. The fair reimbursement issues pose constraints to the
global pathogen reduction system market. Ongoing research and development
efforts will play a crucial role in evaluating these new technologies”, said
Mr. Karan Chechi, Research Director of TechSci Research, a research-based
management consulting firm.
“Pathogen Reduction Systems Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Platelet Pathogen Reduction, Plasma Pathogen Reduction), By Application (Viruses, Fungi, Bacteria), By Product (Automated, Semi-Automated), By End User (Hospitals & Clinics, Ambulatory Care centers, Blood Banks, Others), By Region & Competition, 2020-2030F”, has
evaluated the future growth potential of Global Pathogen Reduction Systems
Market and provides statistics & information on market size, structure and
future market growth. The report intends to provide cutting-edge market
intelligence and help decision makers take sound investment decisions. Besides,
the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in Global Pathogen Reduction
Systems Market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: sales@techsciresearch.com
Website: www.techsciresearch.com